---
title: "A resolution supporting the designation of July 15, 2016, as \"Leiomyosarcoma Awareness Day\"."
identifier: "114-SRES-545"
congress: 114
bill_number: 545
bill_type: "SRES"
version_code: "ats"
version_type: "ats"
bill_url: "https://chamberzero.com/congresses/114/bills/sres/545"
source: "https://www.congress.gov/bill/114th-congress/senate-resolution/545"
site: "Chamber Zero"
site_url: "https://chamberzero.com"
rendered_at: "2026-06-03T23:38:34.289Z"
---
Whereas a soft tissue sarcoma is a rare type of cancer, accounting for approximately 1 percent of newly diagnosed cancers;Whereas Leiomyosarcoma (referred to in this preamble as "LMS") is a malignant subtype of soft tissue sarcoma that originates in smooth muscle, often in the walls of blood vessels;Whereas LMS is highly aggressive and can be found throughout the body, but is especially concentrated in the uterus, abdominal cavity, and extremities;Whereas the National Institutes of Health classifies LMS as a rare disease;Whereas most oncologists will only see a few cases of LMS throughout a career;Whereas the causes of LMS are still unknown;Whereas LMS is largely resistant to standard chemotherapeutic agents, radiation treatment, and current immunotherapies;Whereas multidisciplinary care coordination teams, because of their expertise and experience, are critical to the health of LMS patients;Whereas LMS research will allow medical professionals to improve the quality of care for LMS patients, lead to better clinical outcomes, and promote longer survival for LMS patients; andWhereas increased education and awareness about LMS will contribute to the well-being of the communities of the United States: Now, therefore, be itThat the Senate—
  - (1) supports the designation of July 15, 2016, as "Leiomyosarcoma Awareness Day";
  - (2) recognizes the challenges faced by Leiomyosarcoma patients; and
  - (3) commends the dedication of organizations, volunteers, researchers, and caregivers across the country working to improve the quality of life of Leiomyosarcoma patients and the families of Leiomyosarcoma patients.